What D'Angelo's Story Can Help Us Understand About Pancreatic Cancer

What is on the record

D'Angelo, born Michael Eugene Archer, died on the morning of 14 October 2025 at his home in New York. He was 51.

His family confirmed the death. The Guardian reported that he had been living with pancreatic cancer privately, and its obituary the next day named pancreatic cancer as the cause.

That is the whole of the public record. He never described his stage, his treatment, or the date he was diagnosed, so this page does not either.

What a death like this does is send a great many people to read about a disease they had never looked up. Here is what they find.

A gland in an awkward place

The pancreas is about six inches long and shaped like a thin pear lying on its side. NCI describes three parts: a wide head, a middle body, and a narrow tail. It sits between the stomach and the spine.

It has two jobs. One set of cells makes juices that break food down. A second set, the neuroendocrine cells, makes hormones such as insulin.

Cancer can begin in either. NCI keeps them in separate summaries because they act so differently. The exocrine type, which starts in the juice-making cells, is far more common and is usually found late. Pancreatic neuroendocrine tumors, also called islet cell tumors, are less common and carry a better outlook.

Our explainer on pancreatic cancer walks through both.

Why it is usually found late

NCI's clinical summary gives three reasons, and they stack up.

Early pancreatic cancer causes few noticeable symptoms. The symptoms it does cause look like milder problems, such as pancreatitis or an ulcer. And the gland is tucked behind other organs, so it is hard to see clearly on a scan.

No blood test settles the question either. NCI states that no tumor-specific marker exists for this cancer. CA 19-9, the marker most often drawn, has low specificity, which means it can rise in conditions that are not cancer at all. A normal CA 19-9 does not rule out a return of disease.

The registry shows the result. SEER, the federal cancer surveillance program, records that, among people diagnosed from 2016 through 2022, 15% of pancreatic cancers were found while still inside the pancreas. Fifty-one percent were found after spread to distant organs.

Signs that deserve an appointment

Here is NCI's list of what may appear as the cancer grows:

• Yellowing of the skin or the whites of the eyes, called jaundice
• Pale stools, or urine that has turned dark
• Pain in the upper or middle belly that reaches through to the back
• Weight loss with no explanation
• Loss of appetite
• Fatigue

Two of these carry more weight than the rest.

Jaundice with no pain and no fever is not something to watch for a few weeks. In an adult it should be looked at within days. It often means something is pressing on the bile duct.

Belly pain that bores through to the back, paired with weight you did not try to lose, is the other pairing worth an early appointment. Each alone is common. Together they are not.

NCI's risk list is short: a family history of pancreatic cancer, cigarette smoking, obesity, chronic pancreatitis, and certain inherited gene changes, including BRCA1, BRCA2, PALB2 and ATM.

What treatment involves

The first question is whether the tumor can be removed. NCI calls that judgment crucial, and scans decide it: a helical CT, an MRI, or an endoscopic ultrasound, sometimes with a small camera procedure to look directly.

Surgery is the only route that can clear the disease. NCI is blunt about the arithmetic. The best chance comes when the tumor is truly limited to the pancreas, and that describes fewer than 20% of cases. For people with tumors under 2 cm, no lymph node spread, and no growth past the capsule of the gland, full removal is linked to a five-year survival rate of 18% to 24%.

For everyone else, drugs carry the work. FOLFIRINOX combines leucovorin, fluorouracil, irinotecan and oxaliplatin. In the trial NCI cites, it raised median survival to 11.1 months against 6.8 months for gemcitabine alone. It is also harder to tolerate; about 5% of people on it ran a fever while their white cell count was low.

NCI names comfort-focused care inside the same summary rather than at the end of it: opening a blocked bile duct, opening a blocked stomach outlet, controlling pain, and psychological support. It says plainly that these steps may not extend life, and lists them anyway. Our page on palliative care explains what that looks like day to day.

What the group numbers say

About 67,530 new pancreatic cancer diagnoses and about 52,740 deaths are projected in the United States for 2026. The projection belongs to the American Cancer Society, and SEER republishes it. The median age at diagnosis is 71.

Five-year relative survival across all stages is 13.7% for people diagnosed from 2016 through 2022. By stage it runs 43.6% for localized disease, 17.0% for regional, and 3.4% for distant.

These are averages over tens of thousands of people. They describe a group, not a person, and they trail current treatment by years. Our guide to cancer statistics covers how to read a figure like that.

What this does not mean

D'Angelo was 51, which is well below the median age at diagnosis. That is a fact about one man, not a trend.

Nothing here describes his care. He kept the illness private, which was his to decide, and the reporting does not say what stage he had or what he chose to do about it.

And the survival figures on this page are a record of what happened to a large group, most of them diagnosed after the cancer had already spread. Someone diagnosed today, at a different stage, is not that group.

Sources

• The Guardian: D'Angelo, Grammy-winning neo-soul pioneer, dies aged 51
• The Guardian: D'Angelo obituary
• NCI PDQ: Pancreatic Cancer Treatment (Health Professional Version)
• NCI: Pancreatic Cancer—Patient Version
• NCI SEER Stat Facts: Pancreatic Cancer

How this article was prepared

An AI-assisted editorial system helped prepare this page. No named medical reviewer has reviewed it unless one is listed.

See an error, old source, or unclear wording? Tell us.